tributyrin has been researched along with Neoplasms in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (25.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
de Conti, A; Heidor, R; Moreno, FS; Ong, TP; Ortega, JF | 1 |
Takahashi, N | 1 |
Bauer, K; Chung, EJ; Edelman, MJ; Karp, J; Khanwani, S; Nemieboka, N; Tait, N; Trepel, J; Van Echo, D | 1 |
Conley, BA; Dover, G; Egorin, MJ; Fram, RJ; Rosen, DM; Sausville, EA; Tait, N; Van Echo, DA | 1 |
2 review(s) available for tributyrin and Neoplasms
Article | Year |
---|---|
Anticarcinogenic actions of tributyrin, a butyric acid prodrug.
Topics: Animals; Anticarcinogenic Agents; Butyric Acid; Cell Line, Tumor; Humans; Neoplasms; Prodrugs; Triglycerides | 2012 |
[Induction of cell differentiation and development of new anticancer drugs].
Topics: Acylation; Animals; Antineoplastic Agents; Cell Differentiation; Drug Design; Humans; Ketosteroids; Neoplasm Proteins; Neoplasms; Retinoids; Signal Transduction; Tretinoin; Triglycerides | 2002 |
2 trial(s) available for tributyrin and Neoplasms
Article | Year |
---|---|
Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug.
Topics: Administration, Oral; Adult; Aged; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms; Treatment Outcome; Triglycerides | 2003 |
Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms; Prodrugs; Triglycerides | 1998 |